ArticleInternational journal of molecular sciences2022

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.

Reiko Isa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.